Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ADA 2020: CGM Maker Dexcom Gains CE Mark, Launches G6 Pro While Rivalry With Abbott Builds

Executive Summary

Dexcom’s CEO explained the company’s strategy for continued growth, including marketing opportunities for its G6 and G6 Pro continuous glucose monitors and plans for the next-gen G7 CGM.

You may also be interested in...



Dexcom’s Q2 Earnings Exceed Wall Street Expectations; Holds G7 Launch

Dexcom expects 2020 revenues to reach $1.85bn driven by new patient adoption of its CGM device, but will not launch its next-gen G7 this year. 

ADA 2020: Abbott Expects CGM To Reduce Insulin Needed For Type 2 Diabetes

Research presented at this year’s virtual American Diabetes Association meeting demonstrated the benefits of continuous glucose monitoring for those with type 2 diabetes not taking insulin. Mahmood Kazemi, divisional VP for global medical and scientific affairs at Abbott’s diabetes care tells Medtech Insight how he sees CGM technology transforming the future of diabetes management.

ADA 2020: Tandem Wins FDA Nod For T:Slim Pump Technology In Children; Positive Feedback on Studies

After announcing positive results at the American Diabetes Association conference and an expanded FDA approval for its insulin pump delivery system, Tandem Diabetes Care’s CEO outlines its path forward.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132356

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel